Personalized medicine in pancreatic cancer: Harnessing the potential of mRNA vaccines
Aariz Hussain, Areeba Fareed
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a five-year survival rate of just 7%. Its late diagnosis and limited treatment options contribute to poor outcomes. Immunotherapy has had little success due to PDAC's dense and immunosuppressive tumor environment. Emerging mRNA vaccines, such as autogene cevumeran (BNT122), show promise in enhancing treatment. Preliminary trials have reported prolonged survival with minimal side effects. Despite this progress, the complexity of PDAC remains a significant challenge. Continued research is essential to fully realize the potential of mRNA-based therapies in combating this deadly cancer.
Topics & Concepts
Pancreatic cancerPersonalized medicineMessenger RNAComputational biologyCancerMedicineCancer researchBiologyBioinformaticsVirologyGeneticsInternal medicineGenePancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsRNA modifications and cancer